In 2021, long-acting cabotegravir (LA CAB) was approved by the United States Food and Drug Administration for an indication of pre-exposure prophylaxis in women. This is a first in what is hoped to be a robust pipeline of long-acting antiretroviral agents heralding a new era in HIV prevention. The highly anticipated rollout of this agent among populations of young women with persistently high HIV incidence and fertility rates can be expected to leapfrog efforts to end the AIDS epidemic, protecting young women from new HIV infections and reducing new paediatric infections, which are increasingly attributed to incident maternal infections during pregnancy and breastfeeding.
Authors: Elaine Abrams, Martina Penazzato
In any reproduction of this article there should not be any suggestion that WHO or the article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article’s URL.